Camurus Ab
Clinical trials sponsored by Camurus Ab, explained in plain language.
-
New shot could slow tumor growth in rare gut cancers
Disease control OngoingThis study tests a new, easy-to-use injectable drug (CAM2029) against standard monthly shots for people with advanced neuroendocrine tumors of the gut or pancreas. The goal is to see if the new drug can delay tumor growth or death better than current treatments. About 332 adults …
Phase: PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated May 26, 2026 09:55 UTC
-
New injection could shrink livers and ease pain in rare disease
Disease control OngoingThis study tests a new long-acting octreotide injection (CAM2029) in 71 adults with symptomatic polycystic liver disease. Participants receive weekly or biweekly injections or a placebo for 53 weeks to see if the drug reduces liver size and improves symptoms like bloating, pain, …
Phase: PHASE2, PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated May 18, 2026 12:13 UTC